Cost‐effectiveness of biologics in polyarticular‐course juvenile idiopathic arthritis patients unresponsive to disease‐modifying antirheumatic drugs
- 28 December 2010
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 63 (1), 111-119
- https://doi.org/10.1002/acr.20337
Abstract
Objective Juvenile idiopathic arthritis (JIA) is the most common chronic pediatric rheumatic disease and can have long‐term effects leading to disability in adulthood. Biologics are a new class of drugs increasingly used to treat JIA. The primary study objective was to determine the incremental costs of biologics per additional responder compared to conventional treatment (methotrexate). Methods A separate decision model was created for etanercept, infliximab, adalimumab, and abatacept. The study population consisted of polyarticular‐course JIA patients with a prior inadequate response or intolerance to disease‐modifying antirheumatic drugs (DMARDs). The effectiveness measure was the proportion of patients who had a treatment response at 1 year according to the American College of Rheumatology (ACR) Pediatric 30 (Pedi 30) improvement criteria. Direct and indirect costs were calculated in 2008 Canadian dollars. Incremental cost‐effectiveness ratios and 95% confidence intervals (95% CIs) were calculated for each biologic agent using probabilistic sensitivity analyses. Results The additional costs per additional ACR Pedi 30 responder at 1 year were $26,061 (95% CI $17,070, $41,834), $46,711 (95% CI $30,042, $75,787), $16,204 (95% CI $11,393, $22,608), and $31,209 (95% CI $16,659, $66,220) for etanercept, adalimumab, abatacept, and infliximab, respectively. Conclusion Biologics are more effective than methotrexate in achieving a short‐term response in JIA patients with prior inadequate responses to DMARDs; however, this comes at a high annual cost. Adequate long‐term data with respect to both safety and effectiveness are not currently available, nor are utility estimates. Such data will be important to estimate value for money for treating JIA with biologic drugs over the long term.Keywords
This publication has 29 references indexed in Scilit:
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009Annals Of The Rheumatic Diseases, 2009
- Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter studyClinical Rheumatology, 2008
- Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexateAnnals Of The Rheumatic Diseases, 2008
- Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safetyBMC Musculoskeletal Disorders, 2008
- Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trialsAnnals Of The Rheumatic Diseases, 2008
- Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexateRheumatology, 2007
- JUVENILE IDIOPATHIC ARTHRITISArchives of Disease in Childhood: Education & Practice, 2006
- Long‐term safety and efficacy of etanercept in children with polyarticular‐course juvenile rheumatoid arthritisArthritis & Rheumatism, 2006
- Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor ? monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: Results of an open-label prospective studyArthritis & Rheumatism, 2005
- Preliminary definition of improvement in juvenile arthritisArthritis & Rheumatism, 1997